Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 652

1.

Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with nab-paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma.

Alewine C, Ahmad M, Peer CJ, Hu ZI, Lee MJ, Yuno A, Kindrick JD, Thomas A, Steinberg SM, Trepel JB, Figg WD, Hassan R, Pastan I.

Clin Cancer Res. 2019 Dec 2. pii: clincanres.2586.2019. doi: 10.1158/1078-0432.CCR-19-2586. [Epub ahead of print]

PMID:
31792036
2.

Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brain.

Strope JD, Peer CJ, Sissung TM, Hall OM, Huang PA, Harris EM, Gustafson KR, Henrich CJ, Sigano DM, Pauly GT, Schneider JP, Bates SE, Figg WD.

Cancer Biol Ther. 2019 Nov 10:1-8. doi: 10.1080/15384047.2019.1683324. [Epub ahead of print]

PMID:
31709896
3.

Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer.

Zalazar F, Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, Siervi A.

Curr Pharm Biotechnol. 2019;20(12):1072. doi: 10.2174/138920102012190919103433.

PMID:
31701844
4.

Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.

Hicks KC, Knudson KM, Lee KL, Hamilton DH, Hodge JW, Figg WD, Ordentlich P, Jones FR, Rabizadeh S, Soon-Shiong P, Schlom J, Gameiro SR.

Clin Cancer Res. 2019 Oct 23. doi: 10.1158/1078-0432.CCR-19-0727. [Epub ahead of print]

PMID:
31645354
5.

Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Huang PA, Beedie SL, Chau CH, Venzon DJ, Gere S, Kazandjian D, Korde N, Mailankody S, Landgren O, Figg WD.

Sci Rep. 2019 Oct 16;9(1):14884. doi: 10.1038/s41598-019-51446-9.

6.

Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?

Knechel MA, Schmidt KT, Figg WD.

Cancer Biol Ther. 2019 Sep 18:1-3. doi: 10.1080/15384047.2019.1665395. [Epub ahead of print]

PMID:
31530074
7.

Antibody-drug conjugates for cancer.

Chau CH, Steeg PS, Figg WD.

Lancet. 2019 Aug 31;394(10200):793-804. doi: 10.1016/S0140-6736(19)31774-X. Review.

PMID:
31478503
8.

A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.

Peer CJ, Schmidt KT, Kindrick JD, Eisner JR, Brown VV, Baskin-Bey E, Madan R, Figg WD.

Cancer Chemother Pharmacol. 2019 Oct;84(4):759-770. doi: 10.1007/s00280-019-03908-0. Epub 2019 Jul 31.

PMID:
31367790
9.

A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer.

Komiya T, Memmott RM, Blumenthal GM, Bernstein W, Ballas MS, De Chowdhury R, Chun G, Peer CJ, Figg WD, Liewehr DJ, Steinberg SM, Giaccone G, Szabo E, Kawabata S, Tsurutani J, Rajan A, Dennis PA.

Transl Lung Cancer Res. 2019 Jun;8(3):247-257. doi: 10.21037/tlcr.2019.04.19.

10.

A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.

Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, Morelli MP, Kleiner DE, Steinberg SM, Figg WD, Greten TF, Xie C.

Clin Colorectal Cancer. 2019 Dec;18(4):e349-e360. doi: 10.1016/j.clcc.2019.06.004. Epub 2019 Jul 2.

11.

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.

Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM.

J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3.

12.

PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug.

Li M, Nguyen L, Subramaniyan B, Bio M, Peer CJ, Kindrick J, Figg WD, Woo S, You Y.

J Control Release. 2019 Aug 28;308:86-97. doi: 10.1016/j.jconrel.2019.07.010. Epub 2019 Jul 9.

PMID:
31299262
13.

How do you take your coffee?

Sissung TM, Huang PA, Strope JD, Figg WD.

Lancet Oncol. 2019 Jul;20(7):913-914. doi: 10.1016/S1470-2045(19)30387-0. No abstract available.

PMID:
31267961
14.

Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.

Sissung TM, Huang PA, Hauke RJ, McCrea EM, Peer CJ, Barbier RH, Strope JD, Ley AM, Zhang M, Hong JA, Venzon D, Jackson JP, Brouwer KR, Grohar P, Glod J, Widemann BC, Heller T, Schrump DS, Figg WD.

Mol Pharmacol. 2019 Aug;96(2):158-167. doi: 10.1124/mol.118.114827. Epub 2019 Jun 7.

15.

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion.

Conlon KC, Potter EL, Pittaluga S, Lee CR, Miljkovic MD, Fleisher TA, Dubois S, Bryant BR, Petrus M, Perera LP, Hsu J, Figg WD, Peer CJ, Shih JH, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA.

Clin Cancer Res. 2019 Aug 15;25(16):4945-4954. doi: 10.1158/1078-0432.CCR-18-3468. Epub 2019 May 29.

16.

Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.

Kurmasheva RT, Bandyopadhyay A, Favours E, Del Pozo V, Ghilu S, Phelps DA, Erickson SW, Peer CJ, Figg WD, Smith MA, Houghton PJ.

Pediatr Blood Cancer. 2019 Aug;66(8):e27820. doi: 10.1002/pbc.27820. Epub 2019 May 16. Erratum in: Pediatr Blood Cancer. 2019 Oct;66(10):e27933.

17.

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.

Lampert EJ, Hays JL, Kohn EC, Annunziata CM, Minasian L, Yu M, Gordon N, Sissung TM, Chiou VL, Figg WD, Houston N, Lee JM.

Oncotarget. 2019 Apr 23;10(30):2855-2868. doi: 10.18632/oncotarget.26869. eCollection 2019 Apr 23.

18.

Studies on spiro[4.5]decanone prolyl hydroxylase domain inhibitors.

Holt-Martyn JP, Tumber A, Rahman MZ, Lippl K, Figg W Jr, McDonough MA, Chowdhury R, Schofield CJ.

Medchemcomm. 2019 Mar 1;10(4):500-504. doi: 10.1039/c8md00548f. eCollection 2019 Apr 1. Review.

19.

A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma.

Ramaswami R, Uldrick TS, Polizzotto MN, Wyvill KM, Goncalves P, Widell A, Lurain K, Steinberg SM, Figg WD, Tosato G, Whitby D, Yarchoan R.

Clin Cancer Res. 2019 Jul 15;25(14):4238-4247. doi: 10.1158/1078-0432.CCR-18-3528. Epub 2019 Apr 12.

PMID:
30979736
20.

First-in-human phase 0 study of 111In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Kurdziel KA, Mena E, McKinney Y, Wong K, Adler S, Sissung T, Lee J, Lipkowitz S, Lindenberg L, Turkbey B, Kummar S, Milenic DE, Doroshow JH, Figg WD, Merino MJ, Paik CH, Brechbiel MW, Choyke PL.

J Transl Sci. 2019 Apr;5(2). doi: 10.15761/JTS.1000269. Epub 2018 Jul 13.

21.

Detectible mosaic truncating PPM1D mutations, age and breast cancer risk.

Machiela MJ, Myers TA, Lyons CJ, Koster R, Figg WD Jr, Colli LM, Jessop L, Ahearn TU, Freedman ND, García-Closas M, Chanock SJ.

J Hum Genet. 2019 Jun;64(6):545-550. doi: 10.1038/s10038-019-0589-1. Epub 2019 Mar 8.

PMID:
30850729
22.

Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer.

Sissung TM, Rajan A, Blumenthal GM, Liewehr DJ, Steinberg SM, Berman A, Giaccone G, Figg WD.

PLoS One. 2019 Feb 28;14(2):e0212097. doi: 10.1371/journal.pone.0212097. eCollection 2019.

23.

Insulin potentiation therapy for cancer?

Sissung TM, Schmidt KT, Figg WD.

Lancet Oncol. 2019 Feb;20(2):191-192. doi: 10.1016/S1470-2045(19)30003-8. No abstract available.

PMID:
30712796
24.

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, Kleiner DE, Figg WD, Rytlewski JA, Sanders C, Yusko EC, Wood B, Venzon D, Brar G, Duffy AG, Greten TF, Korangy F.

Cancer Immunol Immunother. 2019 Apr;68(4):599-608. doi: 10.1007/s00262-019-02299-8. Epub 2019 Jan 28.

25.

Alam K et al. (2018) Drug Metabolism Letters; 12, 24-32.

Sissung TM, Chau C, Price DK, Figg WD.

Drug Metab Lett. 2018;12(2):153. doi: 10.2174/1872312812999180724145725.

PMID:
30598062
26.

Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract Cancer.

Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V, Khan J, Wei JS, Agdashian D, Tyagi M, Gangalapudi V, Fioravanti S, Walker M, Anderson V, Venzon D, Figg WD, Sandhu M, Kleiner DE, Morelli MP, Floudas CS, Brar G, Steinberg SM, Korangy F, Greten TF.

Hepatology. 2019 May;69(5):2048-2060. doi: 10.1002/hep.30482. Epub 2019 Mar 10.

PMID:
30578687
27.

Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.

Petrovics G, Price DK, Lou H, Chen Y, Garland L, Bass S, Jones K, Kohaar I, Ali A, Ravindranath L, Young D, Cullen J, Dorsey TH, Sesterhenn IA, Brassell SA, Rosner IL, Ross D, Dahut W, Ambs S, Figg WD, Srivastava S, Dean M.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):406-410. doi: 10.1038/s41391-018-0114-1. Epub 2018 Dec 12.

28.

Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization.

Levy EB, Peer C, Sissung TM, Venkatesan A, Pandalai P, Greten T, Hughes MS, Garcia C, Peretti J, Figg W, Lewis A, Wood B.

J Vasc Interv Radiol. 2019 Jan;30(1):19-22. doi: 10.1016/j.jvir.2018.06.023. Epub 2018 Dec 6.

PMID:
30527657
29.

Reviewing the role of healthy volunteer studies in drug development.

Karakunnel JJ, Bui N, Palaniappan L, Schmidt KT, Mahaffey KW, Morrison B, Figg WD, Kummar S.

J Transl Med. 2018 Dec 4;16(1):336. doi: 10.1186/s12967-018-1710-5. Review.

30.

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.

Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, Landgren O.

JAMA Oncol. 2018 Dec 1;4(12):1781-1783. doi: 10.1001/jamaoncol.2018.5457. No abstract available.

31.

Synthesis, Structural Characterization, and Antiangiogenic Activity of Polyfluorinated Benzamides.

Steinebach C, Ambrożak A, Dosa S, Beedie SL, Strope JD, Schnakenburg G, Figg WD, Gütschow M.

ChemMedChem. 2018 Oct 8;13(19):2080-2089. doi: 10.1002/cmdc.201800263. Epub 2018 Sep 6.

32.

Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models.

Harris EM, Strope JD, Beedie SL, Huang PA, Goey AKL, Cook KM, Schofield CJ, Chau CH, Cadelis MM, Copp BR, Gustafson KR, Figg WD.

Mar Drugs. 2018 Jul 19;16(7). pii: E241. doi: 10.3390/md16070241.

33.

Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases.

Gril B, Paranjape AN, Woditschka S, Hua E, Dolan EL, Hanson J, Wu X, Kloc W, Izycka-Swieszewska E, Duchnowska R, Pęksa R, Biernat W, Jassem J, Nayyar N, Brastianos PK, Hall OM, Peer CJ, Figg WD, Pauly GT, Robinson C, Difilippantonio S, Bialecki E, Metellus P, Schneider JP, Steeg PS.

Nat Commun. 2018 Jul 13;9(1):2705. doi: 10.1038/s41467-018-05030-w.

34.

Precision medicine applications in prostate cancer.

McCrea EM, Lee DK, Sissung TM, Figg WD.

Ther Adv Med Oncol. 2018 Jun 18;10:1758835918776920. doi: 10.1177/1758835918776920. eCollection 2018. Review.

35.

A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat.

Peer CJ, Hall OM, Sissung TM, Piekarz R, Balasubramaniam S, Bates SE, Figg WD.

Cancer Chemother Pharmacol. 2018 Sep;82(3):565-570. doi: 10.1007/s00280-018-3631-7. Epub 2018 Jun 27.

36.

HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer.

Alyamani M, Emamekhoo H, Park S, Taylor J, Almassi N, Upadhyay S, Tyler A, Berk MP, Hu B, Hwang TH, Figg WD, Peer CJ, Chien C, Koshkin VS, Mendiratta P, Grivas P, Rini B, Garcia J, Auchus RJ, Sharifi N.

J Clin Invest. 2018 Aug 1;128(8):3333-3340. doi: 10.1172/JCI98319. Epub 2018 Jun 25.

37.

Antineoplastons: when is enough enough?

Figg WD.

Lancet Oncol. 2018 Jun;19(6):733-734. doi: 10.1016/S1470-2045(18)30338-3. Epub 2018 Jun 1. No abstract available.

PMID:
29893248
38.

Tissue preservation with mass spectroscopic analysis: Implications for cancer diagnostics.

Hall OM, Peer CJ, Figg WD.

Cancer Biol Ther. 2018;19(11):953-955. doi: 10.1080/15384047.2018.1456610. Epub 2018 May 31.

39.

Molecular drivers of metastatic castrate-resistant prostate cancer: New roads to resistance.

Huang PA, Price DK, Figg WD.

Cancer Biol Ther. 2018;19(10):869-870. doi: 10.1080/15384047.2018.1449618. Epub 2018 May 14.

40.

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.

Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Elsayed MSA, Cushman M, Pommier Y.

Mol Cancer Ther. 2018 Aug;17(8):1694-1704. doi: 10.1158/1535-7163.MCT-18-0028. Epub 2018 May 10.

41.

Revisiting 5α-reductase inhibitors and the risk of prostate cancer.

Chau CH, Figg WD.

Nat Rev Urol. 2018 Jul;15(7):400-401. doi: 10.1038/s41585-018-0018-9. Review. No abstract available.

42.

Association Between Thiopurine S-Methyltransferase (TPMT) Genetic Variants and Infection in Pediatric Heart Transplant Recipients Treated With Azathioprine: A Multi-Institutional Analysis.

Green DJ, Duong SQ, Burckart GJ, Sissung T, Price DK, Figg WD Jr, Brooks MM, Chinnock R, Canter C, Addonizio L, Bernstein D, Naftel DC, Zeevi A, Kirklin JK, Webber SA, Feingold B.

J Pediatr Pharmacol Ther. 2018 Mar-Apr;23(2):106-110. doi: 10.5863/1551-6776-23.2.106.

43.

A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma.

Hall OM, Peer CJ, Fitzhugh CD, Figg WD.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jun 1;1086:56-62. doi: 10.1016/j.jchromb.2018.04.016. Epub 2018 Apr 10.

44.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

45.

Design, synthesis and biological assessment of N-adamantyl, substituted adamantyl and noradamantyl phthalimidines for nitrite, TNF-α and angiogenesis inhibitory activities.

Luo W, Tweedie D, Beedie SL, Vargesson N, Figg WD, Greig NH, Scerba MT.

Bioorg Med Chem. 2018 May 1;26(8):1547-1559. doi: 10.1016/j.bmc.2018.01.032. Epub 2018 Feb 10.

46.

Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.

Balasubramaniam S, Redon CE, Peer CJ, Bryla C, Lee MJ, Trepel JB, Tomita Y, Rajan A, Giaccone G, Bonner WM, Figg WD, Fojo T, Piekarz RL, Bates SE.

Anticancer Drugs. 2018 Jun;29(5):457-465. doi: 10.1097/CAD.0000000000000596.

47.

Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques.

Bergamaschi C, Watson DC, Valentin A, Bear J, Peer CJ, Figg WD Sr, Felber BK, Pavlakis GN.

Cytokine. 2018 Aug;108:213-224. doi: 10.1016/j.cyto.2018.01.011. Epub 2018 May 7.

48.

The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma.

Jackson S, Weingart J, Nduom EK, Harfi TT, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert M, Rudek MA, Grossman SA.

Fluids Barriers CNS. 2018 Jan 15;15(1):2. doi: 10.1186/s12987-017-0088-8.

49.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.

Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O.

Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10.

50.

Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Tang L, Platek ME, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Figg WD, Lippman SM, Thompson IM, Ambrosone CB.

Carcinogenesis. 2018 Feb 9;39(2):125-133. doi: 10.1093/carcin/bgx144.

Supplemental Content

Support Center